EGFR and glioblastoma: In these cases, the diagnosis of GBM was based on molecular criteria: 3/4 tumors exhibited EGFR amplification, combined loss of chromosome 10 and gain of chromosome 7 (7+/10− phenotype) and TERT promoter mutation, while EGFR amplification and 7+/10− phenotype was found in the remaining case.